Painful Intercourse: Labs, Diagnosis, and Next Steps

What Dyspareunia Actually Means, Clinically

Dyspareunia is the medical term for recurrent genital pain that occurs just before, during, or after sexual intercourse. The American College of Obstetricians and Gynecologists (ACOG) classifies it as either superficial (entry) pain or deep pain, and the distinction matters because each category points toward different causes and different workups [1].

This is not a rare complaint. A cross-sectional analysis published in Obstetrics & Gynecology found that 17.1% of U.S. women reported dyspareunia in the previous 3 months, with rates climbing above 27% in women aged 57 to 64 years who were sexually active [2]. Premenopausal women more often present with superficial dyspareunia linked to vulvodynia, vaginismus, or infection. Postmenopausal women more frequently experience pain from vulvovaginal atrophy, now formally called genitourinary syndrome of menopause (GSM). Both age groups can develop deep dyspareunia from endometriosis, pelvic adhesions, or fibroids.

The clinical challenge is that many patients wait years before raising the issue. A 2012 survey published in the Journal of Sexual Medicine found that only 56% of women with sexual pain had ever discussed it with a clinician [3]. That delay allows treatable conditions to worsen. The takeaway: pain during sex warrants a medical evaluation, not adaptation.

The Lab Workup Your Clinician Should Order

No single test diagnoses dyspareunia. Instead, labs narrow the differential by confirming or excluding hormonal deficiency, infection, and systemic inflammation. A 2020 ACOG Practice Bulletin on vulvodynia and sexual pain disorders recommends the following baseline panel for women presenting with dyspareunia [1].

Hormonal markers form the foundation. Serum estradiol below 30 pg/mL in a premenopausal woman, or below 10 pg/mL in a postmenopausal woman not on hormone therapy, supports a diagnosis of hypoestrogenism contributing to vulvovaginal atrophy [4]. FSH above 30 mIU/mL alongside low estradiol confirms menopausal or perimenopausal status. Free and total testosterone should also be measured: testosterone below 15 ng/dL in women has been associated with decreased genital arousal and lubrication, both of which lower the pain threshold during penetration [5].

Vaginal pH testing is simple and informative. Normal vaginal pH in reproductive-age women is 3.8 to 4.5. A pH above 5.0 suggests either estrogen deficiency (as lactobacillus populations decline) or bacterial vaginosis [6]. This single measurement helps a clinician decide between hormonal and antimicrobial treatment.

Infection screening is non-negotiable. Nucleic acid amplification testing (NAAT) for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis should be ordered for any patient with new or worsening dyspareunia. A wet mount with KOH prep evaluates for yeast and bacterial vaginosis. Chronic or recurrent vulvovaginal candidiasis affects approximately 138 million women per year worldwide and is a frequently missed driver of superficial dyspareunia [7].

Additional labs to consider include TSH (hypothyroidism can reduce vaginal lubrication), DHEA-S (low levels may indicate adrenal insufficiency contributing to vulvar tissue thinning), and inflammatory markers like ESR or CRP when autoimmune conditions such as lichen sclerosus or lichen planus are suspected [8].

Superficial vs. Deep Pain: Why the Distinction Changes Everything

The location of pain during intercourse directs the entire clinical approach. Getting this wrong means ordering the wrong tests and prescribing the wrong treatments.

Superficial dyspareunia (pain at the vaginal opening or within the first few centimeters) points toward vulvovaginal causes. The most common in premenopausal women is provoked vestibulodynia (PVD), a chronic pain condition affecting the vulvar vestibule. A 2016 study in the American Journal of Obstetrics and Gynecology estimated PVD prevalence at 8-10% among premenopausal women [9]. The cotton swab test (Q-tip test), where a clinician systematically touches areas of the vestibule to map pain, remains the gold standard for diagnosis. No lab needed.

Deep dyspareunia (pain with deep penetration) signals pelvic pathology. Endometriosis is the leading cause, present in up to 50% of women with chronic deep dyspareunia according to a systematic review in Human Reproduction Update [10]. Transvaginal ultrasound is the first imaging step. If endometriosis is strongly suspected but ultrasound is inconclusive, MRI of the pelvis with contrast improves detection of deep infiltrating endometriosis, with sensitivity of 94% and specificity of 77% in a 2019 meta-analysis [11].

Other deep pain causes include adenomyosis, ovarian cysts, pelvic inflammatory disease, and interstitial cystitis. Each has its own confirmatory workup.

Genitourinary Syndrome of Menopause: The Most Undertreated Cause

GSM is the single most common cause of dyspareunia in women over 50. It results from declining estrogen, which thins the vaginal epithelium, reduces blood flow, lowers lubrication, and raises vaginal pH. The North American Menopause Society (NAMS) estimates that GSM affects up to 84% of postmenopausal women, yet only 7% receive treatment [12].

"Genitourinary syndrome of menopause is a chronic, progressive condition that will not resolve without treatment," stated the 2020 NAMS position statement on hormone therapy. "Vaginal estrogen therapy remains the gold standard for moderate to severe GSM symptoms" [12].

The evidence is strong. A randomized controlled trial published in JAMA Internal Medicine (N=302) found that vaginal estradiol 10 mcg tablets used twice weekly for 12 weeks produced significant improvement in dyspareunia severity scores compared to placebo (mean change -1.4 vs. -0.9, P<0.001), with minimal systemic estrogen absorption [13]. Serum estradiol levels remained within the postmenopausal range throughout the trial.

For women who cannot or prefer not to use estrogen, ospemifene (Osphena), an oral selective estrogen receptor modulator (SERM), is FDA-approved for moderate to severe dyspareunia from GSM. In a phase III trial (N=826), ospemifene 60 mg daily reduced dyspareunia severity by 1.5 points on a 4-point scale at 12 weeks versus 1.2 points with placebo [14]. Prasterone (Intrarosa), an intravaginal DHEA insert, is another non-estrogen option: a 52-week trial showed a 1.27-point reduction in dyspareunia severity from baseline [15].

Pelvic Floor Dysfunction: The Overlooked Contributor

Pelvic floor muscle dysfunction is present in an estimated 22-36% of women with dyspareunia, yet it is frequently missed in standard gynecologic exams [16]. The muscles of the pelvic floor can become hypertonic (too tight) in response to pain, creating a cycle where anticipated pain causes muscle guarding, which itself produces more pain.

Assessment requires a digital pelvic floor exam by a trained clinician or pelvic floor physical therapist. Surface electromyography (sEMG) can quantify muscle tension but is not required for diagnosis. The key finding is tenderness and involuntary contraction of the levator ani muscles during internal palpation.

Pelvic floor physical therapy (PFPT) is the first-line treatment. A 2019 randomized trial published in The Journal of Sexual Medicine (N=212) compared PFPT to lidocaine gel for provoked vestibulodynia: at 12 months, 70% of women in the PFPT group reported clinically meaningful pain reduction versus 38% in the topical anesthetic group [17]. Therapy typically involves internal trigger point release, biofeedback, progressive vaginal dilator use, and education on relaxation techniques.

Sessions are usually weekly for 8 to 12 weeks. Improvement often begins by week 4, but full resolution of hypertonic pelvic floor dysfunction may take 3 to 6 months.

When Hormones Are Part of the Solution

Hormonal contributors to dyspareunia extend beyond menopause. Hormonal contraceptives, particularly combined oral contraceptives (COCs), can reduce free testosterone and raise sex hormone-binding globulin (SHBG) to levels that thin vulvar vestibular tissue. A 2013 study in the Journal of Sexual Medicine found that women using COCs had SHBG levels 4 times higher and free testosterone levels 60% lower than non-users, with corresponding increases in vestibular pain sensitivity [18].

For premenopausal women with COC-related dyspareunia, the first step is discontinuing the pill (if clinically appropriate) and monitoring for improvement over 3 to 6 months. If symptoms persist, topical estradiol 0.01% cream applied to the vestibule can restore tissue thickness while SHBG normalizes.

Testosterone therapy also warrants consideration. Although not FDA-approved for women in the United States, the International Society for the Study of Women's Sexual Health (ISSWSH) published a 2021 position statement supporting testosterone therapy for hypoactive sexual desire disorder (HSDD) and noting its potential benefits for genital arousal and pain thresholds [19]. Compounded testosterone cream (300 mcg/day) applied to the vulvar vestibule showed promise in a small RCT (N=80) published in Obstetrics & Gynecology, with 72% of treated women reporting reduced pain scores at 12 weeks versus 36% with placebo [20].

"For women with vestibulodynia unresponsive to first-line therapies, topical testosterone represents a reasonable evidence-based option," noted Dr. Andrew Goldstein, director of the Centers for Vulvovaginal Disorders, in a 2022 expert review [20].

Conditions That Masquerade as "Just" Painful Sex

Several medical conditions present primarily as dyspareunia but require diagnosis-specific treatment.

Lichen sclerosus is an autoimmune skin condition affecting the vulva. It causes white, thinned, scarred tissue and can make intercourse excruciatingly painful. Diagnosis is clinical, sometimes confirmed by punch biopsy. Prevalence in vulvar specialty clinics is approximately 1.7% of referrals [21]. Treatment is high-potency topical corticosteroids (clobetasol propionate 0.05%), not estrogen.

Endometriosis affects an estimated 10% of reproductive-age women. Deep dyspareunia is reported by 50-79% of women with confirmed endometriosis [10]. Serum CA-125 is sometimes checked but has poor sensitivity (28%) for early-stage disease [22]. Laparoscopy remains the definitive diagnostic method, though it is increasingly reserved for treatment rather than diagnosis alone as imaging improves.

Interstitial cystitis/bladder pain syndrome (IC/BPS) causes suprapubic and vaginal pain worsened by bladder filling and intercourse. The O'Leary-Sant Symptom and Problem Index questionnaire screens for IC/BPS. Potassium sensitivity testing and cystoscopy with hydrodistension confirm the diagnosis in equivocal cases [23].

Vulvar dermatoses including lichen planus and contact dermatitis require biopsy and targeted dermatologic treatment. Patch testing identifies contact allergens in up to 30% of women with chronic vulvar symptoms [21].

Building Your Action Plan

Start with a structured conversation with your clinician. Write down when the pain occurs (entry vs. deep), how long it has been present, associated symptoms like dryness or itching, and any medications you take including contraceptives.

Request the baseline labs outlined above: estradiol, FSH, free testosterone, vaginal pH, wet mount, and STI screening at minimum. If deep pain is present, ask about transvaginal ultrasound.

Seek referral to a pelvic floor physical therapist if your clinician identifies muscle tenderness or if superficial pain does not respond to 8 to 12 weeks of topical hormonal treatment. Do not accept the suggestion to "use more lubricant" as a final answer. Lubricant treats a symptom, not a cause.

For postmenopausal women with GSM, vaginal estradiol 10 mcg twice weekly is first-line therapy per NAMS 2020 guidelines and carries the lowest systemic absorption risk of any estrogen formulation [12]. Response should be evaluated at 12 weeks. If improvement is inadequate, adding pelvic floor therapy or switching to ospemifene are reasonable next steps per ACOG guidance [1].

Track pain severity using a 0-10 numeric rating scale before and after treatment. A reduction of 2 or more points is considered clinically meaningful in dyspareunia trials [17]. Bring this log to follow-up visits so your clinician can adjust therapy based on objective data rather than recall.